Newsroom 2018
Everything BrainStorm published in 2018.
Latest from BrainStorm
BrainStorm Issues 2018 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.
BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has expanded its autologous cell manufacturing capacity to produce NurOwn to support clinical trials in additional indications, including a P
FDA Accepts BrainStorm’s NurOwn IND Application for Progressive Multiple Sclerosis
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to ini
BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that a poster presentation highlighting a comprehensive review of ALS clinical trial enrichment strategies will be
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn in Progressive Multiple Sclerosis
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA
BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that it will highlight progress with ongoing preclinical research and their proprietary NurOwn technology platform
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the third quarter and nine months ended September 30, 2018.
BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the third quarter ended September 30, 2018, and provide a corporate update, on Monday, October 29 at 8:30am Eastern Time.
BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that their scientific abstract presented by Dr. James Berry entitled, “MicroRNA Changes in the NurOwn Phase 2 ALS
BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of its executive team will present at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Conference in Clearwate
BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent Office (USPTO) has granted a new US patent titled 'METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPH
BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn Cellular Therapy Platform
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of BrainStorm’s executive team will present and participate on expert panel discussions with industry leaders in Cell & Gene
BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, on Thursday, September 6th at 2:10pm
BrainStorm Appoints Arturo Araya as Chief Commercial Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that is has appointed Arturo O. Araya, M.A., M.B.A., as Chief Commercial Officer, effective immediately. Mr. Araya brings to the BrainStorm team nearl
BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, taking place September 4-6, 2018, at
BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn Therapy for ALS
BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the pre-specified interim analysis of safety outcomes for the first 31 participan
BrainStorm Announces Grant of a New European Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has grante
BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended June 30, 2018, and provide a corporate update, on Monday, July 23 at 8:30am Eastern Time.
BrainStorm Granted Japanese Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant notice from the Japanese Patent Office ("JPO") to issue a patent entitled: "Methods of generating mesenchymal
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn Production
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute (Dana-Farber) as a secon
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph Petroziello as vice president of scientific & corporate communications, and Susan Ward, Ph.D. as head of clinical operations
BrainStorm Provides Update on "Right to Try" Policy
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that after careful evaluation of the newly enacted "Right to Try" (RTT) Act, it will not make NurOwn available under this legislation at this time. T
BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow, June 26 th at 08:30am Eastern Time, to announce its policy in regards to the "Right To Try" legislation.
BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the January 8, 2015 private placement. These holders have e
BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will host a "Right-to-Try" (RTT) discussion call on Thursday, June 7th at 8:15am EDT.
BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the BIO International Convention, taking place June 4-7 in Boston, Massachusetts.
BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill. The "Right-to-Try" bill will enable terminally ill patients who do not meet clini
BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2018.
BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, president and CEO, will present data from the company's Phase 2 clinical study of NurOwn in amyotrophic lateral sclerosis (ALS),
Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its financial results for the first quarter ended March 31, 2018, and provide important corporate updates, on Monday, May 14 at
BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern, M.D., MHSc, Chief Operating Officer and Chief Medical Officer, will be a panelist at the 13th Annual Neurotech Investing & Partnering Co
BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will present at the Alliance for Regenerative Medicine's (ARM) 6th Annual Cell & Gene Therapy Investor D
BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that it has amended the protocol of its Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). Per the protocol a
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H. Appel, M.D., and Amit Bar-Or, M.D., to its scientific advisory board (SAB). Dr. Appel and Dr. Bar-Or are joining Jerold Ch
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, and Dr. Ralph Kern, M.D., PhD., Chief Operating Officer & Chief Medical Officer, will provid
BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and the appointment of Jerold Chun, M.D., Ph.D., to Chair. Chun is an acclaimed neuroscientist an
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for the fourth quarter and fiscal year ended December 31, 2017.
BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the calendar year ended December 31, 2017, and provide important corporate updates.
BrainStorm's NurOwn Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing ALSFRS-R subgroup analyses and innovative micro-RNA biomarker data from the NurOwn ® Phase 2 randomized double-
BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, will provide a corporate overview at the BIO CEO & Investor Conference, being held February
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino, Ph.D., to its board of directors. Dr. Polverino is a highly accomplished senior biopharmaceutical executi
BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, President & CEO, and Dr. Ralph Kern, COO & CMO, will be presenting at Precision Medicine World Conference (PMWC) 2018 Silicon Vall
BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health (MoH) for its Israeli contract manufacturing facility. T
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.